QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:ENTX

Entera Bio (ENTX) Stock Forecast, Price & News

$0.70
+0.02 (+2.92%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.69
▼
$0.71
50-Day Range
$0.59
▼
$0.87
52-Week Range
$0.47
▼
$1.48
Volume
46,215 shs
Average Volume
110,705 shs
Market Capitalization
$20.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Entera Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,318.8% Upside
$10.00 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$24,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.33) to ($0.76) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

739th out of 961 stocks

Biological Products, Except Diagnostic Industry

118th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

ENTX stock logo

About Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ENTX Price History

ENTX Stock News Headlines

September 14, 2023 | americanbankingnews.com
Q3 2023 EPS Estimates for Entera Bio Ltd. Cut by HC Wainwright (NASDAQ:ENTX)
September 13, 2023 | finance.yahoo.com
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
September 21, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
September 12, 2023 | americanbankingnews.com
Entera Bio (NASDAQ:ENTX) Given "Buy" Rating at HC Wainwright
September 5, 2023 | finance.yahoo.com
Entera Bio to Participate in Upcoming Investor Conferences
August 16, 2023 | finance.yahoo.com
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
August 12, 2023 | finanznachrichten.de
Entera Bio Ltd.: Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
August 11, 2023 | finance.yahoo.com
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
September 21, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
June 7, 2023 | finanznachrichten.de
Entera Bio Ltd.: Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
June 7, 2023 | technews.tmcnet.com
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
May 7, 2023 | finance.yahoo.com
Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)
May 6, 2023 | finanznachrichten.de
Entera Bio Ltd.: Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
May 5, 2023 | finance.yahoo.com
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
May 5, 2023 | msn.com
Entera Bio: Q1 Earnings Insights
May 5, 2023 | finance.yahoo.com
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
May 3, 2023 | technews.tmcnet.com
Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
May 3, 2023 | finance.yahoo.com
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
April 27, 2023 | marketwatch.com
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board
April 26, 2023 | finance.yahoo.com
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
April 4, 2023 | msn.com
HC Wainwright & Co. Reiterates Entera Bio (ENTX) Buy Recommendation
April 4, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)
April 3, 2023 | finance.yahoo.com
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
March 31, 2023 | finance.yahoo.com
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
March 31, 2023 | finance.yahoo.com
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
March 23, 2023 | finance.yahoo.com
Entera Bio Regains Compliance with Nasdaq Listing Requirements
March 10, 2023 | finance.yahoo.com
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
See More Headlines
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Company Calendar

Last Earnings
8/11/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTX
CUSIP
N/A
CIK
1638097
Web
www.enterabio.com
Phone
(722) 532-7151
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+1,318.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,070,000.00
Net Margins
-9,754.48%
Pretax Margin
-47,586.36%
Return on Equity
-95.70%
Return on Assets
-83.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.26
Quick Ratio
5.26

Sales & Book Value

Annual Sales
$130,000.00
Price / Sales
156.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
1.72

Miscellaneous

Outstanding Shares
28,800,000
Free Float
26,240,000
Market Cap
$20.30 million
Optionable
Not Optionable
Beta
1.84
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Miranda J. Toledano M.B.A. (Age 46)
    CEO & Director
    Comp: $412.5k
  • Dr. Hillel Galitzer M.B.A. (Age 45)
    Ph.D., Chief Operating Officer
    Comp: $387k
  • Ms. Dana Yaacov-Garbeli CPA (Age 40)
    Chief Financial Officer
  • Dr. Arthur C. Santora II (Age 72)
    M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ENTX Stock - Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings or view top-rated stocks.

What is Entera Bio's stock price forecast for 2023?

1 equities research analysts have issued 1-year target prices for Entera Bio's shares. Their ENTX share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 1,318.8% from the stock's current price.
View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts.

How have ENTX shares performed in 2023?

Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has decreased by 3.5% and is now trading at $0.7048.
View the best growth stocks for 2023 here.

Are investors shorting Entera Bio?

Entera Bio saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 26,600 shares, an increase of 24.9% from the August 15th total of 21,300 shares. Based on an average daily trading volume, of 32,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.1% of the company's stock are sold short.
View Entera Bio's Short Interest.

When is Entera Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ENTX earnings forecast.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) announced its quarterly earnings data on Friday, August, 11th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. Entera Bio had a negative trailing twelve-month return on equity of 95.70% and a negative net margin of 9,754.48%.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca.
View institutional ownership trends.

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $0.70.

How much money does Entera Bio make?

Entera Bio (NASDAQ:ENTX) has a market capitalization of $20.30 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.

This page (NASDAQ:ENTX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -